Print

Lay Description

Empagliflozin and other SGLT2 inhibitors are shown to markedly reduce cardiovascular mortality and hospitalization for heart failure (for both preserved and reduced ejection fraction- when the muscle of the left side of the heart is not pumping as well as normal in high-risk subjects with type 2 diabetes and without type 2 diabetes. We will study the relationship between the improvement in heart (cardiac and myocardial ketones) function after the treatment with Empagliflozin compared to baseline conditions. We will also study the relationship between the improvement in heart (cardiac and myocardial ketones) function after the treatment with Empagliflozin and the reduction of free fatty acids with Acipimox compared to baseline conditions

Category

  • Muscle, Bone and Cartilage
IRB Number
STUDY00000012
NCT Number
NCT # not yet entered

Eligibility

Eligible Ages
18-80
Eligible Genders
All
Accepts Healthy Volunteers

Inclusion Criteria

Heart Failure & Diabetes

Exclusion Criteria

Not Diabetic and Don’t have heart failure

Study Design

Arm Groups

Study Contact

Renata Belfort De Aguiar
210-450-3076
belfortda@uthscsa.edu

Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu

Yuejuan Qin
210-358-7200
qiny@uthscsa.edu

Jemema Rajan
210-567-3208
rajanj@uthscsa.edu

Cynthia Ramirez
210-358-7200
ramirezc8@uthscsa.edu

Jessica Shipley
210-567-3208
shipleyj@uthscsa.edu

Principal Investigator
Ralph DeFronzo